A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
May 12, 2021
End Date
December 8, 2023
Administered By
Duke Cancer Institute
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
May 12, 2021
End Date
December 8, 2023